UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity

EMBO reports, 2018-12, Vol.19 (12), p.n/a

2018

Volltextzugriff (PDF)

IL-12 and IL-23: master regulators of innate and adaptive immunity

Immunological reviews, 2004-12, Vol.202 (1), p.96-105

2004

Volltextzugriff (PDF)

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

The Journal of experimental medicine, 2003-12, Vol.198 (12), p.1951-1957

2003

Volltextzugriff (PDF)

Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)

Journal of medicinal chemistry, 2022-04, Vol.65 (7), p.5300-5316

2022

Volltextzugriff (PDF)

IL-25 regulates Th17 function in autoimmune inflammation

The Journal of experimental medicine, 2007-01, Vol.204 (1), p.161-170

2007

Volltextzugriff (PDF)

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Clinical and translational science, 2022-02, Vol.15 (2), p.442-450

2022

Volltextzugriff (PDF)

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

The Journal of immunology (1950), 2021-04, Vol.206 (7), p.1454-1468

2021

Volltextzugriff (PDF)

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

The Journal of experimental medicine, 2005-01, Vol.201 (2), p.233-240

2005

Volltextzugriff (PDF)

Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis

The Journal of clinical investigation, 2006-05, Vol.116 (5), p.1317-1326

2006

Volltextzugriff (PDF)

PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen‐1 signalling

British journal of pharmacology, 2018-02, Vol.175 (3), p.429-439

2018

Volltextzugriff (PDF)

Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models

ImmunoHorizons, 2021-07, Vol.5 (7), p.581-589

2021

Volltextzugriff (PDF)

Cutting Edge: Modulation of Intestinal Autoimmunity and IL-2 Signaling by Sphingosine Kinase 2 Independent of Sphingosine 1-Phosphate

The Journal of immunology (1950), 2007-11, Vol.179 (9), p.5644-5648

2007

Volltextzugriff (PDF)

PRN1008, a Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura

Blood, 2017-12, Vol.130, p.1052-1052

2017

Volltextzugriff (PDF)

IL-12 and IL-23

Immunological reviews, 2004-12, Vol.202, p.96-105

2004

Volltextzugriff (PDF)

IL-12 and IL-23: master regulators of innate and adaptive immunity: Cytokines and Cytokine Receptors

Immunological reviews, 2004, Vol.202, p.96-105

2004

Volltextzugriff (PDF)

IL-23 drives the expansion of pathogenic ThIL-17 cells required for autoimmune inflammation

Inflammation research, 2005-08, Vol.54 (S2), p.S213-S214

2005

Volltextzugriff (PDF)

Families as Partners in Hospital Error and Adverse Event Surveillance

JAMA pediatrics, 2017-04, Vol.171 (4), p.372

2017

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)
Japanisch
(6)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity

IL-12 and IL-23: master regulators of innate and adaptive immunity

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)

IL-25 regulates Th17 function in autoimmune inflammation

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis

PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen‐1 signalling

Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models

Cutting Edge: Modulation of Intestinal Autoimmunity and IL-2 Signaling by Sphingosine Kinase 2 Independent of Sphingosine 1-Phosphate

PRN1008, a Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura

IL-12 and IL-23

IL-12 and IL-23: master regulators of innate and adaptive immunity: Cytokines and Cytokine Receptors

IL-23 drives the expansion of pathogenic ThIL-17 cells required for autoimmune inflammation

Families as Partners in Hospital Error and Adverse Event Surveillance

Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2 & PRN473 reduces venous thrombosis formation in mice

Suchergebnisse filtern